High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: A population-based Canadian cohort-Reference-Cited by-同舟云学术

High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: A population-based Canadian cohort

Published:2009-11 Issue:11 Volume:33 Page:1463-1468
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Seftel M.D.,Demers A.A.,Banerji V.,Gibson S.B.,Morales C.,Musto G.,Pitz M.W.,Johnston J.B.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference31 articles.

1. Incidence rates of the major leukemia subtypes among US hispanics, blacks, and non-hispanic whites;Matasar;Leuk Lymphoma,2006

2. Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL);Eichhorst;Best Pract Res Clin Haematol,2007

3. Chronic lymphocytic leukemia/small lymphocytic lymphoma;Müller-Hermelink,2008

4. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology;Dores;Br J Haematol,2007

5. Public Health Agency of Canada. Cancer Surveillance Online. Available from URL: http://dsol-smed.phac-aspc.gc.ca/dsol-smed/cancer/index_e.html; 2009 [accessed 21.03.09].

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Secular trends in incidence and mortality of non-Hodgkin’s lymphoma in China, 1990–2019, and predictions to 2030: Outlook for the future burden of disease;Tumori Journal;2024-08-02

2. Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade;Current Oncology;2023-07-05

3. A Non-Canonical Role for the Glycosyltransferase Enzyme UGT2B17 as a Novel Constituent of the B Cell Receptor Signalosome;Cells;2023-05-02

4. Patterns and predictors of referral to the specialized chronic lymphocytic leukemia clinic in Manitoba, Canada;Cancer Epidemiology;2022-12

5. A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada;PharmacoEconomics - Open;2022-11-05